A new model of obsessive-compulsive disorder¹ (OCD) that mirrors both symptoms of the disease and the timing² of its treatment in humans has been created by University of Chicago researchers, according to a new study. Using the model, researchers isolated³ a single neurotransmitter receptor in a specific brain region responsible for their model's OCD-like symptoms, offering new insight into the cause of the disorder. Further research with the model may point the way to new treatments for both OCD and autism, said Nancy Shanahan, PhD, lead author of the paper in Biological Psychiatry⁴.

"Treatment for these people is greatly needed, and there really are very few highly valid⁵ animal models of the disorder," said Shanahan, a postdoctoral researcher at the University of Chicago. "Having one that seems to mimic⁶ the disorder so well, especially in terms of the time course of treatments that work in humans, is potentially very useful for researching novel therapeutics."

Stephanie Dulawa, PhD, assistant professor in the Department of Psychiatry and Behavioral Neuroscience at the University of Chicago Medical Center and senior author of the study, said, "Our model can make accurate predictions about what you see in OCD, and that gives us confidence that the underlying⁸ neurobiology is likely to be similar between the model and the actual disorder."

About 2.2 million people in the United States have been diagnosed with OCD, according to the National Institute of Mental Health. OCD patients struggle with repetitive（重复的） rituals (such as hand-washing, counting and cleaning) and unwanted thoughts that can cause severe anxiety.

Psychiatrists⁹ have found some success treating patients with a class of drugs called serotonin（血清素） reuptake（再吸收） inhibitors (SRIs) initially¹⁰ developed for depression. However, these drugs fail to reduce symptoms in as many as 60 percent of OCD patients and require four to eight weeks of treatment for therapeutic⁷ effects to begin.

"OCD is very mysterious and very prevalent," Shanahan said. "The development of OCD-specific treatments will be an extremely important step toward helping¹¹ these people and preventing the disorder's cost to society."

With an animal model that replicates¹² at least some aspects of OCD, researchers can dig deeper into the specific neurotransmitters and systems involved in the disorder. In Dulawa's laboratory, a team led by Shanahan found inspiration in a drug that activates¹³ the 1b class of receptors for the neurotransmitter serotonin. Clinically, the drug is used to treat migraines, but it is also known to have the unintended effect of increasing anxiety and compulsions in people with OCD.

When the drug was given to mice, they showed highly repetitive patterns of locomotion¹⁴（运动，移动） when placed into an open arena¹⁵. The drug-treated mice also exhibited deficits¹⁶ in prepulse inhibition, a form of startle plasticity thought to measure the brain's ability to filter out intrusive¹⁷ thoughts, which plague OCD patients.